PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial

Phase 3

Completed

Conditions: Gaucher Disease

Interventions: Drug: Taliglucerase alfa

First Posted Date: 2008-06-27

Last Posted Date: 2018-10-04

Lead Sponsor: Pfizer

Target Recruit Count: 45

Registration Number: NCT00705939

Locations: 🇨🇱
Pontificia Universidad Catolica de Chile, Santiago, Chile
🇦🇺
Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Victoria, Australia
🇺🇸
Department of Human Genetics, Emory University School of Medicine, Decatur, Georgia, United States

and more 8 locations

Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma

Phase 4

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Sunitinib Malate (SU011248)

First Posted Date: 2008-06-27

Last Posted Date: 2013-01-18

Lead Sponsor: Pfizer

Target Recruit Count: 105

Registration Number: NCT00706706

Locations: 🇨🇳
Pfizer Investigational Site, Xi'an, China

A Study of PF-04217903 in Patients With Advanced Cancer

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: PF-04217903

First Posted Date: 2008-06-27

Last Posted Date: 2012-06-25

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT00706355

Locations: 🇺🇸
Pfizer Investigational Site, Detroit, Michigan, United States

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

Phase 1

Completed

Conditions: Non-Alcoholic Steatohepatitis(NASH)

Interventions: Drug: Active treatment
Drug: Placebo

First Posted Date: 2008-06-27

Last Posted Date: 2009-08-13

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT00706537

Locations: 🇺🇸
Pfizer Investigational Site, Durham, North Carolina, United States

Nonrestorative Sleep RSQ (Restorative Sleep Questionnaire) Development-- Methodology Study

Terminated

Conditions: Nonrestorative Sleep

Interventions: Procedure: PSG

First Posted Date: 2008-06-26

Last Posted Date: 2019-03-04

Lead Sponsor: Pfizer

Target Recruit Count: 64

Registration Number: NCT00705601

Locations: 🇨🇦
Pfizer Investigational Site, Toronto, Ontario, Canada

Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

Completed

Conditions: Lymphoma, Mantle-Cell
Carcinoma, Renal Cell, Advanced
Gastrointestinal Stroma Tumors

Interventions: Drug: Sunitinib
Drug: Temsirolimus
Drug: Axitinib

First Posted Date: 2008-06-18

Last Posted Date: 2022-12-05

Lead Sponsor: Pfizer

Target Recruit Count: 1520

Registration Number: NCT00700258

Locations: 🇩🇪
Office of Detlef Muller, Bautzen, Germany
🇩🇪
Klotz, Weiden, Germany
🇩🇪
Carsten Lange, Bernburg, Germany

and more 74 locations

Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

Phase 3

Terminated

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: sorafenib
Drug: sunitinib malate

First Posted Date: 2008-06-18

Last Posted Date: 2013-01-14

Lead Sponsor: Pfizer

Target Recruit Count: 1075

Registration Number: NCT00699374

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

Study Evaluating The Use Of Sirolimus In Recipients Of Kidney Allografts From Expanded Criteria Donors (ECD)

Completed

Conditions: Renal Transplantation

Interventions: Drug: Sirolimus

First Posted Date: 2008-06-13

Last Posted Date: 2014-01-22

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT00697112

Locations: 🇦🇷
Pfizer Investigational Site, Tucuman, Argentina

Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects

Phase 1

Completed

Conditions: Healthy
Non-Smoking

Interventions: Drug: varenicline
Drug: Placebo

First Posted Date: 2008-06-10

Last Posted Date: 2009-06-02

Lead Sponsor: Pfizer

Target Recruit Count: 50

Registration Number: NCT00694044

Locations: 🇺🇸
Pfizer Investigational Site, Orlando, Florida, United States

The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy

Phase 2

Completed

Conditions: Cardiomyopathy

Interventions: Drug: Fx-1006A

First Posted Date: 2008-06-10

Last Posted Date: 2013-01-11

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT00694161

Locations: 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy